Value-based agreements could disrupt how we pay for new therapies
WIN MCNAMEE/GETTY IMAGES
Paying for therapies based on the value they provide could revolutionize how medicines are priced and reimbursed in the U.S.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario